#AANAM – Early Parkinson’s Therapy, UCB0599, Well Tolerated in Phase 1b Trial

#AANAM – Early Parkinson’s Therapy, UCB0599, Well Tolerated in Phase 1b Trial

292528

#AANAM – Early Parkinson’s Therapy, UCB0599, Well Tolerated in Phase 1b Trial

UCB’s experimental oral therapy UCB0599 was generally well tolerated in people with mild to moderate Parkinson’s disease and other age-related conditions, a Phase 1b clinical trial reported. Along with its good pharmacokinetic profile, which tracks the therapy’s movement into, through, and out of the body, these findings support UCB0599’s further development as a potential therapy for these patients. An 18-month Phase 2 trial, called ORCHESTRA (NCT04658186), is now recruiting early stage Parkinson’s patients at sites in…

You must be logged in to read/download the full post.